WO2007016095A3 - Cyclooxygenase-2 selective inhibitor compounds comprising nitric oxide enhancing groups, compositions and methods of use - Google Patents

Cyclooxygenase-2 selective inhibitor compounds comprising nitric oxide enhancing groups, compositions and methods of use Download PDF

Info

Publication number
WO2007016095A3
WO2007016095A3 PCT/US2006/028856 US2006028856W WO2007016095A3 WO 2007016095 A3 WO2007016095 A3 WO 2007016095A3 US 2006028856 W US2006028856 W US 2006028856W WO 2007016095 A3 WO2007016095 A3 WO 2007016095A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
nitric oxide
cyclooxygenase
oxide enhancing
cox
Prior art date
Application number
PCT/US2006/028856
Other languages
French (fr)
Other versions
WO2007016095A2 (en
Inventor
David S Garvey
Original Assignee
Nitromed Inc
David S Garvey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc, David S Garvey filed Critical Nitromed Inc
Publication of WO2007016095A2 publication Critical patent/WO2007016095A2/en
Publication of WO2007016095A3 publication Critical patent/WO2007016095A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

The invention describes compositions and kits comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor comprising at least one nitric oxide enhancing group, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating inflammation, pain and fever; (b) treating gastrointestinal disorders and/or improving the gastrointestinal properties of COX-2 selective inhibitors; (c) facilitating wound healing; (d) treating renal and/or respiratory toxicities; (e) treating disorders resulting from elevated levels of cyclooxygenase-2; (f) improving the cardiovascular profile of COX-2 selective inhibitors; (g) treating diseases resulting from oxidative stress; (h) treating endothelial dysfunctions; (j) treating diseases caused by endothelial dysfunctions; (k) treating inflammatory disease states and/or disorders; (1) treating ophthalmic disorders; and (m) treating peripheral vascular diseases. The cyclooxygenase 2 selective inhibitors of the invention are 2(2-((2-chloro-6-fluorophenyl) amino)5-methylphenyl)acetic acid derivatives comprising at least one nitric oxide enhancing group. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors.
PCT/US2006/028856 2005-07-27 2006-07-26 Cyclooxygenase-2 selective inhibitor compounds comprising nitric oxide enhancing groups, compositions and methods of use WO2007016095A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70263905P 2005-07-27 2005-07-27
US60/702,639 2005-07-27

Publications (2)

Publication Number Publication Date
WO2007016095A2 WO2007016095A2 (en) 2007-02-08
WO2007016095A3 true WO2007016095A3 (en) 2008-02-28

Family

ID=37709118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028856 WO2007016095A2 (en) 2005-07-27 2006-07-26 Cyclooxygenase-2 selective inhibitor compounds comprising nitric oxide enhancing groups, compositions and methods of use

Country Status (1)

Country Link
WO (1) WO2007016095A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378771A1 (en) * 2021-05-25 2022-12-01 Louis Habash Modifying the expression level of a gene encoding an cyclooxygenase enzyme by treating a human subject with a nitroxide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
WO2001045703A1 (en) * 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
WO2003094924A1 (en) * 2002-05-10 2003-11-20 Merck & Co., Inc. Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
WO2003103602A2 (en) * 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
WO2001045703A1 (en) * 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
WO2003094924A1 (en) * 2002-05-10 2003-11-20 Merck & Co., Inc. Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
WO2003103602A2 (en) * 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use

Also Published As

Publication number Publication date
WO2007016095A2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2006127591A3 (en) Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
NO20055316D0 (en) New heterocyclic compounds useful in the treatment of inflammatory and allergic disorders, processes for their preparation and pharmaceutical compositions containing such
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
NO332405B1 (en) Compound of 5-substituted quinoline and isoquinoline derivatives, process for their preparation, their use in the preparation of pharmaceutical agents for the treatment of inflammatory disease and pharmaceutical composition comprising the compound.
NO20070387L (en) Quarterly salt CCR2 antagonists
NO20062983L (en) Sulfonamide derivatives for the treatment of diseases
EP2269610A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2007059311A3 (en) Furoxan compounds, compositions and methods of use
WO2004004648A3 (en) Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2007016136A3 (en) Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
EP2266569A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
MX2007009372A (en) Novel compounds ii 2-pyridine derivatives as inhibitors of neutrophile elastase.
NO20083567L (en) Hydantoin derivatives for the treatment of inflammatory disorders
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
CY1123426T1 (en) METHOD FOR OBTAINING MEGLUMINE SALT CRYSTALS OF 1-(5,6-DICHLORO-1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID
ATE478864T1 (en) HYDANTOINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2008097538A8 (en) Therapeutic agents
NO20070247L (en) Amino-5,5-diphenylimidazolone derivatives for inhibition of beta-secretase
JP2007506758A5 (en) 4- (1-benzofuran-3-yl-methylideneaminooxy-propoxy) -benzoic acid derivatives and related compounds as PAI-1 inhibitors for the treatment of disorders of fibrinolytic systems, thrombosis
NO20071577L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory diseases
DE602007005120D1 (en) 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASES OR SUFFERINGS WHICH ARE OF AN INHIBITION FOR THE ACTIVITY OF NEUTROPHIL ELASTASE
WO2010042489A3 (en) Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
WO2007054514A3 (en) Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
DK1592384T3 (en) Cop 1 for the treatment of inflammatory bowel diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06800321

Country of ref document: EP

Kind code of ref document: A2